Cellnovo announces the commercialisation of insulin cartridges following the successful start of large-scale manufacturing at the Flex facility in Althofen, Austria

in portfolio news

Current patients using mass-produced cartridges
Large-scale production capacity secured
Company ready to respond to sustained market demand

Cellnovo Group (“Cellnovo” or the “Company” -- CLNV: EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, today announces the commercialisation of insulin cartridges produced by Flex following the successful start of large-scale manufacturing in Althofen, Austria.

Sophie Baratte, Chief Executive Officer of Cellnovo, commented: “This milestone marks a major turning point for the Company as we are no longer constrained by limited production capacities that have heavily restricted our sales. We can now focus on the commercial lift off of our unique diabetes management system to serve a multi-billion-dollar market.

The Flex-made cartridges are in the hands of existing Cellnovo System users. These cartridges,combined with the superior accuracy of our system, and its real-time connectivity, offer a highly competitive solution to respond to a strong demand. We anticipate a positive impact on our sales over
the coming months.”

Paul Humphries, President, High-Reliability Solutions at Flex, commented: “We are pleased to have successfully completed the last phase of the validation process for the Cellnovo insulin cartridge. This is a significant milestone in our relationship with Cellnovo and now allows for large-scale production.”

Flex’s industrial manufacturing site in Althofen, operating at full capacity, will provide Cellnovo with a 12-fold increase in insulin cartridges produced annually.

The scalability of the Flex production system enables rapid expansion of the Company’s manufacturing capacity. The creation of a second production line in Romania, a copy of the one in Althofen, will be completed in H1 2019 enabling a further increase in production capacity.

Cellnovo has established an international commercial network in ten countries, with a direct sales team in the United Kingdom and France, and in partnership with Air Liquide subsidiaries in other European countries such as Italy, The Netherlands and Spain. In Australia, New Zealand, Israel, Greece, and Cyprus, Cellnovo is working with distributors who have substantial knowledge of the local diabetes markets. The Cellnovo System is reimbursed in all countries. The Company will now focus on developing sales through this network and continue to make its product accessible, globally, through additional distribution agreements.